Julia von Tresckow, MD of University of Cologne, Cologne, Germany, discusses the CLL2-BIG trial, which is one of four trials…
Browsing: Acute Lymphoblastic Leukemia
Clemens Wendtner, MD of Klinikum Schwabing, Munich, Germany, highlights key advances in the field of chronic lymphocytic leukemia (CLL) discussed…
Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany, how to take care of the mental well-being of chronic…
World-renowned MPN expert Dr. Ruben Mesa of Mayo Clinic discusses the recently updated NCCN guidelines that help advise doctors around…
In this video, Drs. Morton Coleman and John P. Leonard summarize the key take-home points presented on lymphoma during Lymphoma…
In this video, Drs. Morton Coleman and Richard R. Furman summarize the key take-home points presented on CLL during Lymphoma…
In this video Drs. Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma…
Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses SABR and immunotherapy.
Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses Utilizing SABR in the oligo-metastatic disease.
Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses SABR in locally advanced RCC and oligo-metastatic disease.
Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses What is the role of SABR in CNS mets in…
Eric Jonasch, MD of MD Anderson gives an overview of several presentations covering the Understanding Molecular Subtypes of Non-Clear Cell…
Chung-Han Lee, MD, PhD, Medical Oncologist, Memorial Sloan Kettering interview on Medullary Renal Cell Carcinoma (RCC): Genomics and Treatment Outcomes.
Ithaar H. Derweesh, M.D., University of California, San Diego discusses neoadjuvant therapy for patients with metastatic disease and extra renal…
Ithaar H. Derweesh, M.D., University of California, San Diego discusses the historical data for neoadjuvant therapy in RCC.
Guru Sonpavde, MD, Associate Professor of Medicine Director, Urologic Oncology, UAB Comprehensive Cancer Center notes that More Single Agent Therapy…
Guru Sonpavde, MD, Associate Professor of Medicine Director, Urologic Oncology, UAB Comprehensive Cancer Center discusses VEGF followed by PD-1 inhibition…
Guru Sonpavde, MD, Associate Professor of Medicine Director, Urologic Oncology, UAB Comprehensive Cancer Center answers the question Why would sequencing…
David McDermott, MD of Dana Farber discusses toxicity concerns with the combination VEGF PD-1.
David McDermott, MD of Dana Farber answers the question Why VEGF + PD-1 are logical choices for combination therapy in…
Naomi B. Haas, MD, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University…
Are memory issues typical for patients with myelofibrosis? Is aspirin the answer? In this Ask the Expert segment, Dr. Prithviraj…
Dr. Sima Porten, MD MPH, Assistant Professor, Department of Urology UCSF answers the question What are some of the limitations…
Dr. Sima Porten, MD MPH, Assistant Professor, Department of Urology UCSF answers the question What patients should be selected for…
Kamran Ahrar, MD, MBA, Professor, Interventional Radiology answers the question Why is renal tumor ablation underutilized?
Kamran Ahrar, MD, MBA, Professor, Interventional Radiology answers the question what is the current role of renal tumor ablation?
hillip M. Pierorazio, MD, Assistant Professor of Urology and Oncology, Brady Urological Institute, Sidney Kimmel Cancer Center, Johns Hopkins Hospital…
Phillip Pierorazio, MD, Assistant Professor of Urology and Oncology, Brady Urological Institute, Sidney Kimmel Cancer Center, Johns Hopkins Hospital outlines…
Dr. Daniel Heng MD @DrDanielHeng University of Calgary discusses genomic investigation in the ASSURE and S-TRAC adjuvant trials.
Daniel Heng, MD University of Calgary @DrDanielHeng describes what is the role of genomic investigation in predicting recurrence of local…
Alexander Kutikov, MD, FACS, Associate Professor of Urologic Oncology Fox Chase Cancer Center answers the question of what is the…
Alexander Kutikov, MD, FACS explains the current standards of care for renal mass biopsies at the 2016 annual International Kidney…
Aly-Khan A. Lalani, MD of the University of Alberta gives a quick overview of the latest in Proton Pump Inhibitors…
Paula Ragan, CEO of X4 Pharmaceuticals gives a quick overview of her presentation at the 2016 annual International Kidney Cancer…
Professor Thomas Powles MBBS, MRCP, MD, Barts Cancer Institute presents Clinical outcomes based on MET expression level in METEOR, a…
Toni K. Choueiri, MD, Director and Disease Center Leader, The Lank Center for Genitourinary Oncology, President of Medical Staff, Dana-Farber…
Brian I. Rini, M.D., Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center presents Axitinib is an Ideal Choice…
Thomas E Hutson, DO, PharmD FACP Director, GU Oncology Program, Co-Director, Urologic Cancer Research and Treatment Center, Texas Oncology/ Baylor…
Nizar M. Tannir, MD, FACP, Professor and Deputy Chair, GU Medical Oncology, MD Anderson presents Cabozantinib is the best salvage…
Saby George, MD, FACP, Associate Professor of Medicine and Oncology, Genitourinary Oncology Program , Roswell Park Cancer Institute presents Nivolumab…
HIF-2 Inhibitor discussion at the 2016 annual International Kidney Cancer Symposium.
… 77 year WF presents with back painHistory of renal cell carcinoma, s/p right radical nephrectomy in 2000T1bN0M0 Clear cell…
Bernard Escudier, Institut Gustave Roussy presents Developing the next generation of studies in RCC at the 2016 annual International Kidney…
James Brugarolas, M.D., Ph.D., Kidney Cancer Program Leader, Virginia Murchison Linthicum Endowed Scholar, Associate Professor of Internal Medicine University of…
Axel Bex, MD, PhD, The Netherlands Cancer Institute presents Durable Responses: How Do We Get There? The role of metastasectomy…
Dylan Martini, MD, Dana-Farber Cancer Institute presents Outcomes in PD-1/PD-L1 inh. responders who discontinued therapy for immune-related adverse events: Analysis…
James J. Hsieh, MD, PhD, Memorial Sloan Kettering Cancer Center presents Differential Overall Survival Results in RECORD-3 Study Based on…
Lana Hamieh, MD, Research Fellow in Medicine (EXT) presents Characterization of Patients with Poor-Risk Metastatic Renal Cell Carcinoma at the…
Jun Gong, Fellow, City of Hope presents Latency of potential treatment-related adverse events among patients treated with TKI/VEGF-directed therapy for…
Jill Rachel Mains, MD, Dept. of Radiology and Oncology, Aarhus University Hospital presents Baseline Low B-value Diffusion-weighted Magnetic Resonance Imaging…